Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03117361
Other study ID # APL-B-022-15
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date May 8, 2017
Est. completion date July 30, 2018

Study information

Verified date November 2020
Source PharmaMar
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center, open-label, single arm, non-comparative phase II trial, designed to evaluate the efficacy of plitidepsin in combination with bortezomib and dexamethasone in patients with Multiple Myeloma (MM) double refractory to bortezomib and lenalidomide.


Description:

This is a multi-center, open-label, single arm, non-comparative phase II trial, designed to evaluate the efficacy of plitidepsin in combination with bortezomib and dexamethasone in patients with MM double refractory to bortezomib and lenalidomide.The primary endpoint will be overall response rate (ORR), including stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and partial response (PR). Approximately 64 evaluable patients will be needed for the evaluation of the primary endpoint, ORR. An early futility analysis will be performed with the efficacy data collected from the first 20 evaluable patients. The futility analysis will commence once patient number 20 has completed two full treatment cycles. Patient recruitment will not be halted during the conduct of this futility analysis.


Recruitment information / eligibility

Status Terminated
Enrollment 10
Est. completion date July 30, 2018
Est. primary completion date July 30, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients must give written informed consent (IC) in accordance with institutional and local guidelines. 2. Age = 18 years. 3. Patients must have a confirmed diagnosis of MM according to the Durie and Salmon criteria. 4. Patients must have measurable disease defined as any of the following: 1. Serum M-protein = 0.5 g/dL or = 0.2 g/24-h urine light chain (UFLC) excretion. 2. In patients who lack measureable M-protein in serum or urine, i.e., serum M-protein < 0.5 g/dL and urine M-protein < 0.2 g/24 h, serum free light chain (SFLC) levels are most informative. SFLC levels can be used only if the baseline SFLC ratio is abnormal (<0.26 or >1.65), indicating clonality. In addition, the baseline SFLC level must be =10 mg/dl of the appropriate involved light chain isotype. 3. When applicable, measurable soft tissue plasmacytoma = 2 cm, by either physical examination and/or applicable radiological evaluation (i.e., magnetic resonance imaging [MRI], computed tomography [CT]-scan). 5. Prior autologous and/or allogeneic hematopoietic stem cell transplantation (HSCT) patients are allowed. Patients must not have acute/chronic graft-versus-host disease (GVHD) or be receiving immunosuppressive therapy at least 90 days before the onset of treatment with the trial drug(s). 6. Patients must have received previous treatment with bortezomib and lenalidomide and be refractory to both. 7. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 2. 8. Recovery to grade = 1 from any non-hematological adverse event (AE) derived from previous treatment (if present, alopecia and peripheral neuropathy must be grade <1). 9. Laboratory data: 1. Hemoglobin = 8 g/dL. 2. Absolute neutrophil count (ANC) = 1,000 cells/mm3 (1.0 x 109/L) (= 0.5 x 109/L if due to extensive bone marrow [BM] involvement by = 50% of plasma cells in BM biopsy). Screening of ANC should be independent of granulocyte- and granulocyte/macrophage-colony stimulating factor (G-CSF and GM-CSF) support for at least one week and of pegylated G-CSF for at least two weeks. 3. Platelet count = 50,000/mm3 (50.0 x 109/L) for patients in whom < 50% of the BM nucleated cells are plasma cells. 4. Platelet count = 25,000/mm3 (25.0 x 109/L) for patients in whom = 50% of BM nucleated cells are plasma cells. 5. Serum total bilirubin < 1.5 x institutional upper limit of normal (ULN) (except when Gilbert syndrome is clearly documented and other liver function tests are within normal levels). 6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3.0 x institutional ULN and alkaline phosphatase (AP) = 2.5 x institutional ULN. 7. Creatinine clearance (CrCl) > 30 mL/min, measured or calculated according to Cockcroft and Gault's formula. 8. Albumin = 2.5 g/dl. 10. Evidence of non-childbearing status for women of childbearing potential (WOCBP): WOCBP must have a negative serum or urine pregnancy test within seven days prior to enrolment and must agree to use a highly effective contraceptive measure throughout the trial and during six months after treatment discontinuation. Male patients enrolled in the study should also use contraceptive methods during and after treatment discontinuation. 11. Left ventricular ejection fraction (LVEF) = 45%. 12. Patients must have a BM assessment within three weeks prior to enrolment. Exclusion Criteria: 1. Previous treatment with plitidepsin. 2. Active or metastatic primary malignancy other than MM. 3. Serious concomitant systemic disorders that would compromise the safety of the patient or the patient's ability to complete the trial, including the following specific conditions: 1. Uncontrolled psychiatric illness or medical illness that the Investigator feels will compromise the patient's tolerance of the trial medication. 2. Significant non-neoplastic liver disease. 3. Uncontrolled endocrine diseases (i.e., requiring relevant changes in medication within the last month, or hospital admission within the last three months). 4. Uncontrolled systemic infection. 5. Acute infiltrative pulmonary and pericardial disease. 4. Other relevant cardiac conditions: 1. Symptomatic arrhythmia (excluding anemia-related grade = 2 sinusal tachycardia) or any arrhythmia requiring ongoing treatment, and/or prolonged grade = 2 QT-QTc; or presence of unstable atrial fibrillation (according to the National Cancer Institute Common Terminology Criteria for the Classification of Adverse Events [NCI-CTCAE] v4.0). Patients on treatment for stable atrial fibrillation are allowed, provided they do not meet any other cardiac or prohibited drug exclusion criterion. 2. History or presence of unstable angina, myocardial infarction, valvular heart disease, cardiac amyloidosis or congestive heart failure within the last 12 months. 3. Uncontrolled arterial hypertension (= 150/100 mmHg) despite optimal medical therapy. 4. Previous treatment with doxorubicin at cumulative doses of > 400 mg/m², or equivalent. 5. History of hypersensitivity reactions and/or intolerance to bortezomib, polyoxyl 35 castor oil, mannitol, boron or dexamethasone. 6. Myopathy or any clinical situation that causes significant and persistent elevation of creatine phosphokinase (CPK) (> 2.5 ULN) in two different determinations performed within one week of each other. 7. Grade = 1 neuropathy (either bortezomib-related or not) according to NCI-CTCAE v4.0. 8. Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patients' participation in this trial. 9. Pregnant and/or lactating women. 10. Known active human immunodeficiency virus (HIV) infection (HIV testing is not required unless infection is clinically suspected). 11. Active hepatitis B or C virus (HBV or HCV) infection. 12. Treatment with any Investigational Medicinal Product (IMP) in the 30 days before inclusion in the trial. 13. Concomitant medications that include corticosteroids, chemotherapy (CT), or other therapy that is or may be active against myeloma. Concurrent corticosteroids are allowed as an equivalent to a prednisone dose of = 10 mg daily, administered as an antiemetic or as premedication for blood products. 14. Wash-out periods after the end of the previous therapy: 1. Nitrosoureas must be discontinued six weeks prior to Cycle (C) 1, D1. 2. Thirty days for other CTs and 15 days for other biological agents prior to C1 D1. 3. Thirty days after the end of any prior radiation or radionuclide therapy (six weeks in the case of prior extensive external beam radiation, with more than 25% of BM distribution). 15. Plasma cell leukemia at the time of trial entry. 16. Disease-related symptomatic hypercalcemia despite optimal medical therapy. 17. Limitation of the patient's ability to comply with the treatment or follow-up protocol. 18. Contraindication to use steroids.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
plitidepsin
Patients received plitidepsin as a 3-hour i.v. infusion at a dose of 5 mg/m2 on Days 1 and 15 every Four Weeks.
Bortezomib
BTZ as a 3-5 second bolus s.c. injection at a dose of 1.3 mg/m2 on Days 1, 4, 8 and 11 every four weeks
Dexamethasone
DXM orally at a dose of 40 mg/day on Days 1, 8, 15 and 22 every four weeks

Locations

Country Name City State
France CHRU de Lille - Hôpital Claude Huriez Lille
France Institut Gustave Roussy Villejuif
Italy Policlinico Vittorio Emanuele Hospital Catania
Italy Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Meldola
Italy Azienda Ospedaliera Città della Salute e della Scienza di Torino Torino
Spain Hospital Universitario Germans Trias i Pujol Badalona Barcelona
Spain Institut Català d´Oncologia Girona Girona
Spain Institut Català d´Oncologia L´Hospitalet Hospitalet de Llobregat
Spain Hospital General Universitario J.M. Morales Meseguer Murcia
Spain Clinica Universidad de Navarra Pamplona Navarra
Spain Hospital Universitario de Salamanca Salamanca
Spain Complexo Hospitalario Universitario de Santiago Santiago De Compostela
Spain Complejo Hospitalario Regional Virgen Del Rocio Sevilla

Sponsors (1)

Lead Sponsor Collaborator
PharmaMar

Countries where clinical trial is conducted

France,  Italy,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Response Partial response (PR): =50% reduction in serum M-protein and reduction of 24-hour urine M-protein by 90% or to <200 mg/24h Minimal response (MR): =25% but =49% reduction of serum M-protein and reduction of 24h urine M-protein 50-89%.
Progressive disease (PD): 25% increase from the lowest response value in any of the following: serum M-protein, urine M-protein, BM plasma cell percentage, or difference in the kappa and lambda FLC. PD also diagnosed when an increase size or new bone lesions Stable disease (SD): not meet the criteria for PR, MR or PD Primary analysis should have been done once a total of 64 patients have received plitidepsin+BTZ+DXM with one futility analysis planned after the inclusion of 20 evaluable patients that had completed two full treatment cycles. Only 10 patients were treatedand 8 evaluable for the primary endpoint (ORR according to IMWG criteria). As a result of slow patient accrual, the study was closed before reaching the target enrollment
From the date of first drug administration to the date of at least one disease assessment, up to 100 weeks
Primary Overall Response Rate The primary endpoint was overall response rate (ORR) (including stringent complete response [sCR], complete response [CR], very good partial response [VGPR] and partial response [PR]), according to the IMWG response criteria. From the date of first drug administration to the date of at least one disease assessment, up to 100 weeks
Secondary Clinical Benefit Rate Clinical benefit rate defined as minimal response or better From the date of first drug administration to the date of at least one disease assessment, up to 100 weeks
Secondary Disease Control Rate Disease control rate defined as stable disease [SD] or better From the date of first drug administration to the date of at least one disease assessment, up to 100 weeks
Secondary Duration of Response Duration of Response defined as the time, in months, from the date of first documentation of response to the date of disease progression. Response was assessed according to the IMWG classification response criteria. From the date of first documentation of response to the date of disease progression, up to 100 weeks
Secondary Time to Progression Time to progression (TTP) was defined as the time, in months, from the date of the first infusion to the date of documented PD or death due to PD. TTP was to be censored on the date of the last tumor assessment or on the date of the first drug administration if there were no tumor assessments.
Progressive disease (PD): 25% increase from the lowest response value in any of the following: serum M-protein, urine M-protein, BM plasma cell percentage, or difference in the kappa and lambda FLC. PD also diagnosed when an increase size or new bone lesions.
From the date of the first infusion to the date of documented PD or death due to PD, up to 100 weeks
Secondary Percentage of Participants With Progression Disease at 3 Months Progression disease was defined as documented PD or death due to PD Progressive disease (PD): 25% increase from the lowest response value in any of the following: serum M-protein, urine M-protein, BM plasma cell percentage, or difference in the kappa and lambda FLC. PD also diagnosed when an increase size or new bone lesions. From the date of the first infusion to the date of documented PD or death due to PD, up to 3 months
Secondary Percentage of Participants With Progression Disease at 6 Months Progression disease was defined as documented PD or death due to PD. Progressive disease (PD): 25% increase from the lowest response value in any of the following: serum M-protein, urine M-protein, BM plasma cell percentage, or difference in the kappa and lambda FLC. PD also diagnosed when an increase size or new bone lesions From the date of the first infusion to the date of documented PD or death due to PD, up to 6 months
Secondary Percentage of Participants With Progression Disease at 12 Months Progression disease was defined as documented PD or death due to PD. Progressive disease (PD): 25% increase from the lowest response value in any of the following: serum M-protein, urine M-protein, BM plasma cell percentage, or difference in the kappa and lambda FLC. PD also diagnosed when an increase size or new bone lesions. From the date of the first infusion to the date of documented PD or death due to PD, up to 12 months
Secondary Progression-free Survival Progression-free survival (PFS) was defined as the time, in months, from the date of first drug administration to the date of documented PD, or death (of any cause). If any patient was lost to follow-up before PD or received another antitumor therapy, PFS was to be censored on the date of the last tumor assessment. If there were no tumor assessments, these parameters were to be censored on the date of the first drug administration.
Progressive disease (PD): 25% increase from the lowest response value in any of the following: serum M-protein, urine M-protein, BM plasma cell percentage, or difference in the kappa and lambda FLC. PD also diagnosed when an increase size or new bone lesions.
From the date of first drug administration to the date of documented PD, or death (of any cause), up to 100 weeks
Secondary Percentage of Participants With Progression-free Survival at 3 Months Progression-free Survival was defined as documented PD, or death of any cause. Progressive disease (PD): 25% increase from the lowest response value in any of the following: serum M-protein, urine M-protein, BM plasma cell percentage, or difference in the kappa and lambda FLC. PD also diagnosed when an increase size or new bone lesions. From the date of first drug administration to the date of documented PD, or death (of any cause), up to 3 months
Secondary Percentage of Participants With Progression-free Survival at 6 Months Progression-free Survival was defined as documented PD, or death of any cause. Progressive disease (PD): 25% increase from the lowest response value in any of the following: serum M-protein, urine M-protein, BM plasma cell percentage, or difference in the kappa and lambda FLC. PD also diagnosed when an increase size or new bone lesions. From the date of first drug administration to the date of documented PD, or death (of any cause), up to 6 months
Secondary Percentage of Participants With Progression-free Survival at 12 Months Progression-free survival (PFS) was defined as the time, in months, from the date of first drug administration to the date of documented PD, or death (of any cause). If any patient was lost to follow-up before PD or received another antitumor therapy, PFS was to be censored on the date of the last tumor assessment. If there were no tumor assessments, these parameters were to be censored on the date of the first drug administration Progressive disease (PD): 25% increase from the lowest response value in any of the following: serum M-protein, urine M-protein, BM plasma cell percentage, or difference in the kappa and lambda FLC. PD also diagnosed when an increase size or new bone lesions. From the date of first drug administration to the date of documented PD, or death (of any cause), up to 12 months
Secondary Event-free Survival Event-free survival (EFS) was defined as the time, in months, from the date of first drug administration to the date of onset of the first drug-related event leading to treatment discontinuation, documented PD or death. The censoring rules defined above for PFS were used for EFS From the date of first drug administration to the date of onset of the first drug-related event leading to treatment discontinuation, documented PD or death, up to 100 weeks
Secondary Percentage of Participants With Event-free Survival at 3 Months Event-free survival (EFS) was defined as the first drug-related event leading to treatment discontinuation, documented PD or death.
rogressive disease (PD): 25% increase from the lowest response value in any of the following: serum M-protein, urine M-protein, BM plasma cell percentage, or difference in the kappa and lambda FLC. PD also diagnosed when an increase size or new bone lesions.
From the date of first drug administration to the date of onset of the first drug-related event leading to treatment discontinuation, documented PD or death, up to 3 months
Secondary Percentage of Participants With Event-free Survival at 6 Months Event-free survival (EFS) was defined as the first drug-related event leading to treatment discontinuation, documented PD or death.
Progressive disease (PD): 25% increase from the lowest response value in any of the following: serum M-protein, urine M-protein, BM plasma cell percentage, or difference in the kappa and lambda FLC. PD also diagnosed when an increase size or new bone lesions.
From the date of first drug administration to the date of onset of the first drug-related event leading to treatment discontinuation, documented PD or death, up to 6 months
Secondary Percentage of Participants With Event-free Survival at 12 Months Event-free survival (EFS) was defined as the first drug-related event leading to treatment discontinuation, documented PD or death.
Progressive disease (PD): 25% increase from the lowest response value in any of the following: serum M-protein, urine M-protein, BM plasma cell percentage, or difference in the kappa and lambda FLC. PD also diagnosed when an increase size or new bone lesions.
From the date of first drug administration to the date of onset of the first drug-related event leading to treatment discontinuation, documented PD or death, up to 12 months
Secondary Overall Survival Overall survival (OS) was defined as the time, in months, from the date of first drug administration to the date of death (of any cause) or last patient contact (in this case, survival was to be censored on that date). From the date of first drug administration to the date of death (of any cause) or last patient contact, up to 100 weeks
Secondary Percentage of Participants With Overall Survival at 6 Months Overall survival (OS) was defined as death of any cause. From the date of first drug administration to the date of death (of any cause) or last patient contact, up to 6 months
Secondary Percentage of Participants With Overall Survival at 12 Months Overall survival (OS) was defined as death of any cause. From the date of first drug administration to the date of death (of any cause) or last patient contact, up to 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1